Paradigm shifts and concerns in supply chain, warranties, liability and IP - Ernst-Jan Louwers - Louwers IP|Technology Advocaten - www.louwersadvocaten.nl
Re-/bioprinting the law - 28 January 2015 - Ernst-Jan Louwers
1. Re-/bioprinting the law
Paradigm shifts and concerns in supply
chain, warranties, liabilities and IP
Ernst-Jan Louwers
3D Bioprinting Conference
MECC Maastricht, 28 January 2015
2. Eindhoven The Hague
Who are we?
⢠Lean and mean niche firm
⢠Specialised and no nonsense
⢠Focus on intersection of law and
technology
3. What do we do?
Protect and attack
Enable and empower
5. âBy 2016, 3D printing of tissues
and organs (bioprinting) will
cause a global debate about
regulating the technology or
banning it for both human and
nonhuman use.â
Gartner 2013
6. Shift happensâŚ
What about you?
Are you aware of your legal position and
risks in R&D or commercialisation?
Where is your role in the value chain of
the future?
7. Agenda
⢠Topics to consider
⢠Intellectual property
⢠(Product)liability
⢠Roadmap to market
⢠Joint R&D and (open) innovation
8. Itâs not easyâŚ
Many topics to consider
Ownership
Body parts or
cells
Implants
Data
Intellectual
property and
secrecy
Compliance
Existing
regulations*
Ethics and
codes of
conduct
Fundamental
rights
Privacy
R&D
Collaboration
Background
IP and
knowhow
Foreground IP
and
knowhow
Valorisation
and
exploitation
Supply chain
Changing
rolls
Relationships
Risk
Liability
* Among others EU Directives and US FDA regulations on
admission and classification of medical devices.
9. Why?
Awareness, assessment and precaution!
Intellectual
Property
Material
Method
Output
Liability
Risk
Who?
When?
Supply
chain
R&D
Factory
Reseller
17. Starting material patentable?
⢠Products of nature: in principle not
patentable
⢠Isolated human genes?
o US: NO, butâŚ
o AMP/Myriad case
o Europe: until now YES
o Comparable to plant breeding
o Public opinionâŚ
⢠Nonhuman (synthetic): YES
18. Methods patentable?
⢠Technology of bioprinting: YES
⢠Products directly resulting from method?
o in principle YES (âproduct by processâ)
21. Tissue and parts: IP protected?
Can you patent an ear?
Printed using human cells from Lieuwe van
Gogh, great-grandson of Vincent van
Gogh (sharing 1/16th of the same genes)
22. Output: IP protected?
Can you patent an ear?
⢠Printed human tissue/organs patentable?
o function and structure significantly different from
human cells
o not simply âproducts of natureâ
⢠Inventive step?
⢠Novelty?
o right ear is same as left ear - no novelty?
⢠Output of method: âproduct by processâ
24. ⢠3D printed jaw patentable?
⢠3D printed joints patentable?
⢠Shape and function?
⢠Or only the material?
BUT again:
⢠Method and output as âproduct by processâ
⢠Mixtures and intermediate result may be
patentable
Protheses and dental & IP
28. Changing the gameâŚ
⢠Hospitals to become factories
⢠Doctors becoming engineers
⢠Engineers becoming doctors
⢠Dentists printing implants
⢠Industry becoming suppliers of human
tissue and spares
33. Spare parts and implants
⢠Print it yourself protheses�
⢠Limited warranty?
⢠Product liability?
⢠Remove?
⢠Recall?
⢠Existing regulations and classifications?
34.
35. Not only business plan
Roadmap to market
But also legal plan
Material Method Hardware
Software
and data
Output
36. Letâs roll the dice:
whatever your game isâŚ
Protect Contract Manage
RepositionReconsider Reorganize
37. Share (and save)
⢠Sharing
o best practices
o legal insights
o policies
⢠Agreements
o consortium agreements
o licenses
o R&D
38. Joint R&D â Open innovation
AgreementsâŚ
⢠Input
o Efforts
o Background knowhow and IP
⢠Output
o Foreground knowhow and IP
o Exploitation
⢠Governance (steering committee)
⢠Secrecy and patents
⢠Liability
⢠(De)escalation
39. Rolling the dice
What about you?
Where do you stand in the value chain
of the future?
Reconsider your (legal) position and
relationships!
40. ⢠IP strategy: offensive - defensive
⢠Assessment and compliance
⢠Formalisation of your role
⢠Joint R&D - consortium agreements
⢠Valorisation, licensing and
commercialisation
Legal roadmap